160 related articles for article (PubMed ID: 35993110)
21. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
[TBL] [Abstract][Full Text] [Related]
22. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
[No Abstract] [Full Text] [Related]
23. MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance.
Gao X; Chen G; Gao C; Zhang DH; Kuan SF; Stabile LP; Liu G; Hu J
Mol Oncol; 2017 Jun; 11(6):628-639. PubMed ID: 28306189
[TBL] [Abstract][Full Text] [Related]
24. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
[TBL] [Abstract][Full Text] [Related]
25. ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
Saad MI; Alhayyani S; McLeod L; Yu L; Alanazi M; Deswaerte V; Tang K; Jarde T; Smith JA; Prodanovic Z; Tate MD; Balic JJ; Watkins DN; Cain JE; Bozinovski S; Algar E; Kohmoto T; Ebi H; Ferlin W; Garbers C; Ruwanpura S; Sagi I; Rose-John S; Jenkins BJ
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30833304
[TBL] [Abstract][Full Text] [Related]
26. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
[TBL] [Abstract][Full Text] [Related]
27. BRAF
Reischmann N; Andrieux G; Griffin R; Reinheckel T; Boerries M; Brummer T
Oncogene; 2020 Sep; 39(38):6053-6070. PubMed ID: 32792685
[TBL] [Abstract][Full Text] [Related]
28. β-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer.
Kuo TL; Cheng KH; Shan YS; Chen LT; Hung WC
Theranostics; 2019; 9(2):324-336. PubMed ID: 30809277
[No Abstract] [Full Text] [Related]
29. SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
Lu H; Liu C; Velazquez R; Wang H; Dunkl LM; Kazic-Legueux M; Haberkorn A; Billy E; Manchado E; Brachmann SM; Moody SE; Engelman JA; Hammerman PS; Caponigro G; Mohseni M; Hao HX
Mol Cancer Ther; 2019 Jul; 18(7):1323-1334. PubMed ID: 31068384
[TBL] [Abstract][Full Text] [Related]
30. Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.
Kawaguchi Y; Hinoi T; Saito Y; Adachi T; Miguchi M; Niitsu H; Sasada T; Shimomura M; Egi H; Oka S; Tanaka S; Chayama K; Sentani K; Oue N; Yasui W; Ohdan H
J Gastroenterol; 2016 May; 51(5):447-57. PubMed ID: 26361962
[TBL] [Abstract][Full Text] [Related]
31. Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.
Tabibzadeh A; Tameshkel FS; Moradi Y; Soltani S; Moradi-Lakeh M; Ashrafi GH; Motamed N; Zamani F; Motevalian SA; Panahi M; Esghaei M; Ajdarkosh H; Mousavi-Jarrahi A; Niya MHK
Sci Rep; 2020 Oct; 10(1):18713. PubMed ID: 33127962
[TBL] [Abstract][Full Text] [Related]
32. Concurrent Activation of Kras and Canonical Wnt Signaling Induces Premalignant Lesions That Progress to Extrahepatic Biliary Cancer in Mice.
Nagao M; Fukuda A; Omatsu M; Namikawa M; Sono M; Fukunaga Y; Masuda T; Araki O; Yoshikawa T; Ogawa S; Masuo K; Goto N; Hiramatsu Y; Muta Y; Tsuda M; Maruno T; Nakanishi Y; Taketo MM; Ferrer J; Tsuruyama T; Nakanuma Y; Taura K; Uemoto S; Seno H
Cancer Res; 2022 May; 82(9):1803-1817. PubMed ID: 35247892
[TBL] [Abstract][Full Text] [Related]
33. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
Das K; Gunasegaran B; Tan IB; Deng N; Lim KH; Tan P
Cancer Lett; 2014 Oct; 353(2):167-75. PubMed ID: 25086186
[TBL] [Abstract][Full Text] [Related]
34. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.
Deng N; Goh LK; Wang H; Das K; Tao J; Tan IB; Zhang S; Lee M; Wu J; Lim KH; Lei Z; Goh G; Lim QY; Tan AL; Sin Poh DY; Riahi S; Bell S; Shi MM; Linnartz R; Zhu F; Yeoh KG; Toh HC; Yong WP; Cheong HC; Rha SY; Boussioutas A; Grabsch H; Rozen S; Tan P
Gut; 2012 May; 61(5):673-84. PubMed ID: 22315472
[TBL] [Abstract][Full Text] [Related]
35. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
36. A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling.
Hwang JH; Yoon J; Cho YH; Cha PH; Park JC; Choi KY
Int J Cancer; 2020 May; 146(10):2877-2890. PubMed ID: 31605540
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations.
Blaj C; Schmidt EM; Lamprecht S; Hermeking H; Jung A; Kirchner T; Horst D
Cancer Res; 2017 Apr; 77(7):1763-1774. PubMed ID: 28202525
[TBL] [Abstract][Full Text] [Related]
38. Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification.
Wang Y; Chu F; Lin J; Li Y; Johnson N; Zhang J; Gai C; Su Z; Cheng H; Wang L; Ding X
J Ethnopharmacol; 2021 Oct; 279():114399. PubMed ID: 34246740
[TBL] [Abstract][Full Text] [Related]
39. Myocardial KRAS(G12D) expression does not cause cardiomyopathy in mice.
Dalin MG; Zou Z; Scharin-Täng M; Safari R; Karlsson C; Bergo MO
Cardiovasc Res; 2014 Feb; 101(2):229-35. PubMed ID: 24259500
[TBL] [Abstract][Full Text] [Related]
40. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
Park H; Cho SY; Kim H; Na D; Han JY; Chae J; Park C; Park OK; Min S; Kang J; Choi B; Min J; Kwon JY; Suh YS; Kong SH; Lee HJ; Liu ET; Kim JI; Kim S; Yang HK; Lee C
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12492-7. PubMed ID: 26401016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
